search
Back to results

Efficacy & Safety Comparison of Epiduo With Doxycycline Versus Vehicle With Isotretinoin in the Treatment of Severe Acne (POWER)

Primary Purpose

Acne

Status
Completed
Phase
Phase 3
Locations
Canada
Study Type
Interventional
Intervention
Epiduo/Tactuo
vehicle gel
doxycycline 200mg
Isotretinoin
Sponsored by
Galderma R&D
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Acne

Eligibility Criteria

12 Years - 35 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Male or female subject of any race, aged 12 to 35 years inclusive
  2. Subject weighing between 50 and 110 kg
  3. Subject with severe acne (IGA at least 4), which in the opinion of the investigator is appropriate for treatment with oral isotretinoin (severe nodular acne, severe inflammatory acne, recalcitrant acne; all unresponsive to conventional first line therapies)
  4. Subject with at least 5 nodules on the face

Exclusion Criteria:

  1. Subject with clinically abnormal results to blood testings performed at screening
  2. Subject with acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne, etc.), pyoderma faciale, sinus tracks
  3. Female subject who is pregnant, nursing or planning a pregnancy during the study
  4. Subject with known history of hepatic and/or renal insufficiency, to be confirmed by blood testings
  5. Subject with known metabolic or structural bone disease (for 12-17 years old population)
  6. Subject with bowel disease and/or with hypervitaminosis A
  7. Subject who presents with treated or untreated depression or has a history of depression including a family history of major depression
  8. Subject with a wash-out period from baseline for topical treatment on the face less than : Corticosteroids, antibiotics, antibacterials, antiseptics, retinoids, other anti-inflammatory drugs or other acne treatments (2 weeks); Cosmetic procedures (1 week); Photodynamic therapy and laser therapy for acne (3 months)
  9. Subject with a wash-out period from baseline for systemic treatment less than: Corticosteroids, antibiotics (4 weeks),Progesterone for contraception (3 months); Spironolactone(3 months); Other acne treatments (6 months);Cyproterone acetate(6 months)

Sites / Locations

  • Galderma investigational site
  • Galderma investigational site
  • Galderma investigational site
  • Galderma investigational site
  • Galderma investigational site
  • Galderma investigational site
  • Galderma investigational site
  • Galderma investigational site
  • Galderma investigational site
  • Galderma investigational site
  • Galderma investigational site
  • Galderma investigational site
  • Galderma investigational site
  • Galderma investigational site
  • Galderma investigational site
  • Galderma investigational site
  • Galderma investigational site
  • Galderma investigational site
  • Galderma investigational site
  • Galderma investigational site
  • Galderma investigational site
  • Galderma investigational site
  • Galderma investigational site
  • Galderma investigational site
  • Galderma investigational site
  • Galderma investigational site

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Epiduo/Tactuo + doxycycline 200mg

Isotretinoin + vehicle gel

Arm Description

Outcomes

Primary Outcome Measures

The Primary Outcome is Overall Success, a Composite Endpoint Including Efficacy and Safety Measurements
Overall success is reached when the 2 following criteria are fulfilled : Overall efficacy: reduction of at least 75% of number of nodules at the end of treatment Safe treatment: Absence of any listed safety issues

Secondary Outcome Measures

Full Information

First Posted
November 16, 2011
Last Updated
February 16, 2021
Sponsor
Galderma R&D
search

1. Study Identification

Unique Protocol Identification Number
NCT01474590
Brief Title
Efficacy & Safety Comparison of Epiduo With Doxycycline Versus Vehicle With Isotretinoin in the Treatment of Severe Acne
Acronym
POWER
Official Title
Efficacy and Safety Comparison of Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel Associated With 200 mg Doxycycline Capsules Versus Vehicle Gel Associated With Isotretinoin Capsules in the Treatment of Severe Acne
Study Type
Interventional

2. Study Status

Record Verification Date
August 2017
Overall Recruitment Status
Completed
Study Start Date
November 2011 (undefined)
Primary Completion Date
July 2013 (Actual)
Study Completion Date
August 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Galderma R&D

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Non-inferiority, randomized, controlled, multi-center, investigator-blind, parallel-group comparison study in subjects with severe acne vulgaris on the face.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acne

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Investigator
Allocation
Randomized
Enrollment
266 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Epiduo/Tactuo + doxycycline 200mg
Arm Type
Experimental
Arm Title
Isotretinoin + vehicle gel
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
Epiduo/Tactuo
Intervention Description
topical to the face, once daily in the evening
Intervention Type
Other
Intervention Name(s)
vehicle gel
Intervention Description
topical to the face, once daily in the evening
Intervention Type
Drug
Intervention Name(s)
doxycycline 200mg
Intervention Description
oral, 2 capsules once daily in the morning with aglass of water and with food
Intervention Type
Drug
Intervention Name(s)
Isotretinoin
Intervention Description
oral, 0.5mg/kg/day for a period of four weeks, adjusted to 1 mg/kg/day for the four following months.
Primary Outcome Measure Information:
Title
The Primary Outcome is Overall Success, a Composite Endpoint Including Efficacy and Safety Measurements
Description
Overall success is reached when the 2 following criteria are fulfilled : Overall efficacy: reduction of at least 75% of number of nodules at the end of treatment Safe treatment: Absence of any listed safety issues
Time Frame
20 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
12 Years
Maximum Age & Unit of Time
35 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female subject of any race, aged 12 to 35 years inclusive Subject weighing between 50 and 110 kg Subject with severe acne (IGA at least 4), which in the opinion of the investigator is appropriate for treatment with oral isotretinoin (severe nodular acne, severe inflammatory acne, recalcitrant acne; all unresponsive to conventional first line therapies) Subject with at least 5 nodules on the face Exclusion Criteria: Subject with clinically abnormal results to blood testings performed at screening Subject with acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne, etc.), pyoderma faciale, sinus tracks Female subject who is pregnant, nursing or planning a pregnancy during the study Subject with known history of hepatic and/or renal insufficiency, to be confirmed by blood testings Subject with known metabolic or structural bone disease (for 12-17 years old population) Subject with bowel disease and/or with hypervitaminosis A Subject who presents with treated or untreated depression or has a history of depression including a family history of major depression Subject with a wash-out period from baseline for topical treatment on the face less than : Corticosteroids, antibiotics, antibacterials, antiseptics, retinoids, other anti-inflammatory drugs or other acne treatments (2 weeks); Cosmetic procedures (1 week); Photodynamic therapy and laser therapy for acne (3 months) Subject with a wash-out period from baseline for systemic treatment less than: Corticosteroids, antibiotics (4 weeks),Progesterone for contraception (3 months); Spironolactone(3 months); Other acne treatments (6 months);Cyproterone acetate(6 months)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jerry Tan
Organizational Affiliation
Windsor Clinical Research Inc.
Official's Role
Principal Investigator
Facility Information:
Facility Name
Galderma investigational site
City
Ajax
Country
Canada
Facility Name
Galderma investigational site
City
Barrie
Country
Canada
Facility Name
Galderma investigational site
City
Calgary
Country
Canada
Facility Name
Galderma investigational site
City
Edmonton
Country
Canada
Facility Name
Galderma investigational site
City
Halifax
Country
Canada
Facility Name
Galderma investigational site
City
Hamilton
Country
Canada
Facility Name
Galderma investigational site
City
Markham
Country
Canada
Facility Name
Galderma investigational site
City
Montreal
Country
Canada
Facility Name
Galderma investigational site
City
Newmarket
Country
Canada
Facility Name
Galderma investigational site
City
Oakville
Country
Canada
Facility Name
Galderma investigational site
City
Oshawa
Country
Canada
Facility Name
Galderma investigational site
City
Peterborough
Country
Canada
Facility Name
Galderma investigational site
City
Quebec city
Country
Canada
Facility Name
Galderma investigational site
City
Richmond Hill
Country
Canada
Facility Name
Galderma investigational site
City
Saint-Hyacinthe
Country
Canada
Facility Name
Galderma investigational site
City
Saint-John's
Country
Canada
Facility Name
Galderma investigational site
City
Saskatoon
Country
Canada
Facility Name
Galderma investigational site
City
St John's
Country
Canada
Facility Name
Galderma investigational site
City
Sudbury
Country
Canada
Facility Name
Galderma investigational site
City
Surrey
Country
Canada
Facility Name
Galderma investigational site
City
Toronto
Country
Canada
Facility Name
Galderma investigational site
City
Vancouver
Country
Canada
Facility Name
Galderma investigational site
City
Waterloo
Country
Canada
Facility Name
Galderma investigational site
City
Windsor
Country
Canada
Facility Name
Galderma investigational site
City
Winnipeg
Country
Canada
Facility Name
Galderma investigational site
City
Woodbridge
Country
Canada

12. IPD Sharing Statement

Citations:
PubMed Identifier
24934963
Citation
Tan J, Humphrey S, Vender R, Barankin B, Gooderham M, Kerrouche N, Audibert F, Lynde C; POWER study group. A treatment for severe nodular acne: a randomized investigator-blinded, controlled, noninferiority trial comparing fixed-dose adapalene/benzoyl peroxide plus doxycycline vs. oral isotretinoin. Br J Dermatol. 2014 Dec;171(6):1508-16. doi: 10.1111/bjd.13191. Epub 2014 Oct 28.
Results Reference
derived

Learn more about this trial

Efficacy & Safety Comparison of Epiduo With Doxycycline Versus Vehicle With Isotretinoin in the Treatment of Severe Acne

We'll reach out to this number within 24 hrs